acquired
Stage
About
Audentes Therapeutics was a biotechnology company developing AAV-based gene therapies targeting rare neuromuscular diseases. The company advanced gene-replacement programs for inherited disorders and was acquired by Astellas Pharma in 2019.
Explore Audentes Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.